BIOTRONIK and GenesisCare Partner to Improve Heart Disease Therapy

Global Medical Device Company and Leader in Cardiology Care Pool Their Health Care Expertise in Australia

BERLIN, Germany and SYDNEY, Australia, June 21, 2018 – Today BIOTRONIK and GenesisCare started a three-year strategic partnership to enhance outcomes for cardiac patients in Australia. The new partners will initiate interdisciplinary research projects focusing on better data sharing, care pathways and integration, as well as tracking outcomes.

“With the necessary technology and know-how, we aim to improve patient outcomes with more responsive, personalised and appropriate care,” explained Prof. Stephen Worthley, Executive Manager of Cardiology at GenesisCare. “This could lead to fewer adverse events, earlier detection of preventable problems and reduced need for hospitalisation.”

Cardiac patients can benefit from this new approach in terms of fewer hospital visits and complications, and lower mortality. This ultimately translates into lower therapy costs, benefiting patients, and also health insurers.

“Our partnership aims to overcome obstacles we face when acting alone,” commented Jan Ewert, Managing Director of BIOTRONIK Australia and New Zealand. “We look forward to collaborating with GenesisCare to work towards a common goal: redefining how patients receive the best possible care.”

GenesisCare comprises the largest group of private practice cardiologists in Australia. The organisation has established systems to monitor and measure patient outcomes. BIOTRONIK, a global producer of cardio and endovascular medical products, will contribute its vast technological knowledge to the partnership.

Related articles

Southampton cancer centre awarded ‘Outstanding’ CQC rating

New study shows MRI-guided radiotherapy could double survival rates for people with inoperable pancreatic cancer

Honouring Clinical Excellence & Leadership: GenesisCare Launches Inaugural Global Physician Recognition Program

GenesisCare Appoints Seven Leading Oncologists to Chair its Global Research Committees